[go: up one dir, main page]

PT1009436E - Derivado de acridina para aumentar a biodisponibilidade oral do taxol - Google Patents

Derivado de acridina para aumentar a biodisponibilidade oral do taxol

Info

Publication number
PT1009436E
PT1009436E PT98947501T PT98947501T PT1009436E PT 1009436 E PT1009436 E PT 1009436E PT 98947501 T PT98947501 T PT 98947501T PT 98947501 T PT98947501 T PT 98947501T PT 1009436 E PT1009436 E PT 1009436E
Authority
PT
Portugal
Prior art keywords
biodisponibility
acridine
derived
increase
taxol
Prior art date
Application number
PT98947501T
Other languages
English (en)
Inventor
Jan H M Schellens
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT1009436E publication Critical patent/PT1009436E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PT98947501T 1997-09-05 1998-09-03 Derivado de acridina para aumentar a biodisponibilidade oral do taxol PT1009436E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718903.9A GB9718903D0 (en) 1997-09-05 1997-09-05 Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (1)

Publication Number Publication Date
PT1009436E true PT1009436E (pt) 2004-03-31

Family

ID=10818634

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98947501T PT1009436E (pt) 1997-09-05 1998-09-03 Derivado de acridina para aumentar a biodisponibilidade oral do taxol

Country Status (15)

Country Link
US (2) US6469022B1 (pt)
EP (1) EP1009436B1 (pt)
JP (2) JP4516688B2 (pt)
KR (1) KR100579030B1 (pt)
AT (1) ATE253360T1 (pt)
AU (1) AU751085B2 (pt)
BR (1) BR9812179A (pt)
CA (1) CA2302568C (pt)
DE (1) DE69819525T2 (pt)
DK (1) DK1009436T3 (pt)
ES (1) ES2210823T3 (pt)
GB (1) GB9718903D0 (pt)
PT (1) PT1009436E (pt)
TR (1) TR200000586T2 (pt)
WO (1) WO1999012570A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
EP0994706B1 (en) * 1997-05-27 2005-11-02 Ivax Research, Inc. Compositions for administering taxanes orally to human patients and their use
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
EP1749540B1 (en) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7417070B2 (en) * 2003-05-22 2008-08-26 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
WO2006021932A1 (en) 2004-08-27 2006-03-02 Koninklijke Philips Electronics, N.V. Electronically and remotely controlled pill and system for delivering at least one medicament
JP2008521794A (ja) * 2004-11-29 2008-06-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム
JP6230772B2 (ja) * 2008-02-18 2017-11-15 シュトコ・ツェーン・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 患者に対する薬物の投与
JP5681861B2 (ja) * 2008-03-31 2015-03-11 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ センサを有する嚥下型カプセルを作成する方法
US9067011B2 (en) 2008-06-19 2015-06-30 MEDIMETRICS Personalized Drug Delivery B.V. Device for delivery of powder like medication in a humid environment
EP2303391B1 (en) * 2008-06-25 2014-08-13 Medimetrics Personalized Drug Delivery B.V. Electronic pill comprising a plurality of medicine reservoirs
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
US10201552B2 (en) 2013-09-05 2019-02-12 Howard University Method of increasing the bioavailability of an HIV drug
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283038B6 (cs) * 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP0994706B1 (en) * 1997-05-27 2005-11-02 Ivax Research, Inc. Compositions for administering taxanes orally to human patients and their use
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (en) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs

Also Published As

Publication number Publication date
US20030013731A1 (en) 2003-01-16
DK1009436T3 (da) 2004-03-08
US6803373B2 (en) 2004-10-12
EP1009436B1 (en) 2003-11-05
EP1009436A2 (en) 2000-06-21
KR20010023670A (ko) 2001-03-26
AU9439498A (en) 1999-03-29
WO1999012570A2 (en) 1999-03-18
TR200000586T2 (tr) 2000-09-21
GB9718903D0 (en) 1997-11-12
US6469022B1 (en) 2002-10-22
AU751085B2 (en) 2002-08-08
CA2302568A1 (en) 1999-03-18
DE69819525T2 (de) 2004-09-23
CA2302568C (en) 2010-06-22
JP2001515872A (ja) 2001-09-25
JP4516688B2 (ja) 2010-08-04
JP2010059185A (ja) 2010-03-18
ES2210823T3 (es) 2004-07-01
ATE253360T1 (de) 2003-11-15
KR100579030B1 (ko) 2006-05-12
BR9812179A (pt) 2000-07-18
DE69819525D1 (de) 2003-12-11
WO1999012570A3 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
PT1009436E (pt) Derivado de acridina para aumentar a biodisponibilidade oral do taxol
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
DZ2495A1 (fr) Formule nouvelle de l'oméprazole-s.
CY2007024I2 (el) Kαινοφανη παραγωγα 3.3-διαφαινυλοπροπυλινων
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
FI19992555A (fi) Antibakteerisia oksatosolidinoniaineita, joilla on tiokarbonyylifunktionaalisuus
DZ2514A1 (fr) Dérivés substitués en c-4'de9-désoxo-9a-aza-9a-homoérythromycine a.
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
DE60032780D1 (de) Tetrahydroquinolin-derivate
AR038427A2 (es) Compuestos 15-alquil-14-hidroxilo de marcfortina y parahercuamida
BR9804027A (pt) Novos beta-ceto ésteres
IS2212B (is) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
FI962976A (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
AR027349A1 (es) Derivados de amidas heterociclicas
FR2773489B1 (fr) Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
NO20013715D0 (no) Karbamatderivater av diaryl 1,3,4-oksadiazolon
BR0012592A (pt) Composto, uso dos compostos, combinação, e, preparação farmacêutica para uso oral ou parenteral
ITPR970056A0 (it) Macchina per l'applicazione di silicone su calze autoreggenti.
ECSP972052A (es) Quinoxalinadionas
NO996392L (no) Angiogenese-inhiberende 5-substituerte-1,2,4-tiadiazolyl- derivater
IT1310279B1 (it) Raddrizzatore di flusso d'aria a doppia corona di contropale.